AgMedica Bioscience Inc., a licensed producer of cannabis for medicinal and adult-use consumers, has announced that it has received approval from Health Canada to extend its existing cultivation and processing license to phase two of its Riverview facility expansion.
Company officials say this approval will allow AgMedica to add a further 12 flowering rooms and increase the cultivation capacity of the facility to between 26,000 and 30,000 kg per year, more than tripling its current capacity.
“I am very pleased that AgMedica has received Health Canada approval for our phase two facility expansion,” stated Dr. Trevor Henry, AgMedica’s CEO, in a press release.
“We gain nearly four times the productive capacity and are better positioned to continue helping improve the quality of life for all of our patients by providing superior, consistent, quality medication.”
Receipt of this approval represents another key milestone in AgMedica’s path toward becoming a global leader in the development and commercialization of cannabis and cannabis-derived products designed to support client health and wellness, company officials say.
Since late 2017, the Company has successfully secured the regulatory approvals required to harvest and sell cannabis, which has contributed to the ongoing growth and enhancement of the business.
In addition to the phase two expansion approval, the Company also confirms that on August 2, 2019, it was granted a medical sales license for its Heritage location, which enables AgMedica to better facilitate healthy living for its clients through a portfolio of products that includes CBD, THC and Balanced varieties.
